SUPRIYA LIFESCIENCE LTD (SUPRIYA) financials

SUPRIYA LIFESCIENCE LTD (SUPRIYA) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]

Market Cap: ₹7,131Cr.
Current Price: ₹886
Stock P/E: 35.9
ROE: 19.1%
ROCE: 25.2%
Book Value: ₹149
Dividend Yield: 0.11%
52W High / Low: ₹1,086/546

In Jun 2026, SUPRIYA LIFESCIENCE LTD (SUPRIYA) reported sales ₹190 Cr and net profit ₹24 Cr.

Annual TTM: sales ₹873 Cr, net profit ₹198 Cr.

Shareholding: Promoters 68.30% (Sep 2026), FIIs 6.45% (Sep 2026), DIIs 5.47% (Sep 2026), Public 19.80% (Sep 2026), No. of Shareholders 78,561% (Sep 2026).

SUPRIYA quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	166	186	184	145	200	206	277	190
Expenses	101	120	117	93	127	134	179	142
Operating Profit	65	66	68	52	73	72	98	47
OPM %	39%	36%	37%	36%	36%	35%	35%	25%
Other Income	3	2	3	3	3	2	3	3
Interest	0	1	0	1	0	0	0	0
Depreciation	5	5	6	6	7	7	8	9
Profit before tax	62	63	64	47	68	67	92	41
Tax %	26%	25%	21%	27%	26%	26%	19%	41%
Net Profit	46	47	50	35	50	50	74	24
EPS in Rs	5.73	5.81	6.26	4.32	6.27	6.17	9.22	2.99
Raw PDF	—	—	—	—	—	—	—	—

SUPRIYA profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	312	391	530	461	570	696	828	873
Expenses	213	218	316	332	394	436	533	583
Operating Profit	98	173	214	129	176	261	295	290
OPM %	32%	44%	40%	28%	31%	37%	36%	33%
Other Income	11	5	8	9	11	10	11	11
Interest	7	4	4	3	5	2	3	2
Depreciation	6	7	10	12	16	20	28	31
Profit before tax	96	167	207	123	166	248	275	268
Tax %	24%	26%	27%	27%	28%	24%	24%	—
Net Profit	73	124	152	90	119	188	209	198
EPS in Rs	10.02	16.89	18.86	11.17	14.80	23.35	25.98	24.65
Dividend Payout %	20%	3%	3%	5%	5%	4%	4%	—

SUPRIYA balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	15	15	15	16	16	16	16	16
Reserves	79	134	254	600	683	799	981	1,182
Borrowings	90	82	72	27	22	5	5	5
Other Liabilities	69	105	105	92	98	101	115	154
Total Liabilities	253	336	445	735	820	921	1,117	1,357
Fixed Assets	85	99	100	190	262	310	453	689
CWIP	35	40	79	43	68	149	148	36
Investments	0	0	0	0	25	64	63	99
Other Assets	133	197	267	502	466	399	453	534
Total Assets	253	336	445	735	820	921	1,117	1,357

SUPRIYA cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	49	117	76	49	64	113	165	186
Cash from Investing Activity	5	-25	-47	-60	-124	-174	-152	-176
Cash from Financing Activity	-50	-29	-15	150	-10	-22	-8	-10
Net Cash Flow	4	62	15	139	-70	-83	4	-0
Free Cash Flow	54	92	29	-11	-44	-32	2	34
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	97%	146%	61%	51%	73%	86%	86%	84%

SUPRIYA shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	68.30%	68.30%	68.30%	68.30%	68.30%	68.30%	68.30%	68.30%
FIIs	6.52%	7.19%	6.78%	5.46%	5.19%	5.16%	6.18%	6.45%
DIIs	4.93%	4.26%	4.86%	5.22%	5.00%	5.70%	5.30%	5.47%
Public	20.25%	20.25%	20.08%	21.02%	21.49%	20.83%	20.21%	19.80%
No. of Shareholders	89,394	91,051	91,928	87,912	85,099	81,161	82,082	78,561

SUPRIYA key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	79	60	69	79	67	71	70	97
Inventory Days	77	130	206	172	234	140	205	229
Days Payable	110	130	145	91	130	98	129	159
Cash Conversion Cycle	45	61	130	160	171	114	146	167
Working Capital Days	-5	-40	28	117	168	157	144	147
ROCE %	37%	50%	60%	43%	19%	22%	27%	25%

SUPRIYAUpdated 18 Oct 2026, 6:08

Supriya Lifescience Ltd

SUPRIYAUpdated 18 Oct 2026, 6:08

Market Cap

₹7,131Cr.

Current Price

₹886

High / Low

₹1,086/546

Stock P/E

35.9

ROE19.1%

ROCE25.2%

Book Value₹149

Face Value₹2.00

Dividend Yield0.11%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	132	1	88	3	4	43	33	29	3.54
Sep 2023	140	0	108	2	4	30	20	24	2.97
Dec 2023	140	0	99	3	4	40	26	30	3.7
Mar 2024	158	1	103	2	4	53	31	37	4.59
Jun 2024	161	0	98	2	5	60	25	45	5.55
Sep 2024	166	0	101	3	5	62	26	46	5.73
Dec 2024	186	1	120	2	5	63	25	47	5.81
Mar 2025	184	0	117	3	6	64	21	50	6.26
Jun 2025	145	1	93	3	6	47	27	35	4.32
Sep 2025	200	0	127	3	7	68	26	50	6.27
Dec 2025	206	0	134	2	7	67	26	50	6.17
Mar 2026	277	0	179	3	8	92	19	74	9.22
Jun 2026	190	0	142	3	9	41	41	24	2.99

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2017	184	12	166	7	5	8	30	6	0.77
Mar 2018	213	11	191	9	5	14	40	9	1.19
Mar 2019	278	10	213	8	5	57	31	39	5.39
Mar 2020	312	7	213	11	6	96	24	73	10.02
Mar 2021	391	4	218	5	7	167	26	124	16.89
Mar 2022	530	4	316	8	10	207	27	152	18.86
Mar 2023	461	3	332	9	12	123	27	90	11.17
Mar 2024	570	5	394	11	16	166	28	119	14.8
Mar 2025	696	2	436	10	20	248	24	188	23.35
Mar 2026	828	3	533	11	28	275	24	209	25.98
TTM	873	2	583	11	31	268	—	198	24.65

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	68.3%
FIIs	6.45%
DIIs	5.47%
Public	19.8%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	68.3%	4.56%	5.39%	21.77%
Mar 2024	68.3%	5.37%	5.3%	21.04%
Jun 2024	68.3%	4.95%	5.48%	21.27%
Sep 2024	68.3%	6.03%	5.45%	20.22%
Dec 2024	68.3%	6.52%	4.93%	20.25%
Mar 2025	68.3%	7.19%	4.26%	20.25%
Jun 2025	68.3%	6.78%	4.86%	20.08%
Sep 2025	68.3%	5.46%	5.22%	21.02%
Dec 2025	68.3%	5.19%	5%	21.49%
Mar 2026	68.3%	5.16%	5.7%	20.83%
Jun 2026	68.3%	6.18%	5.3%	20.21%
Sep 2026	68.3%	6.45%	5.47%	19.8%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2017	15	31	140	55	241	89	36	0	117	241
Mar 2018	15	40	130	60	245	91	34	0	120	245
Mar 2019	15	79	90	69	253	85	35	0	133	253
Mar 2020	15	134	82	105	336	99	40	0	197	336
Mar 2021	15	254	72	105	445	100	79	0	267	445
Mar 2022	16	600	27	92	735	190	43	0	502	735
Mar 2023	16	683	22	98	820	262	68	25	466	820
Mar 2024	16	799	5	101	921	310	149	64	399	921
Mar 2025	16	981	5	115	1117	453	148	63	453	1117
Mar 2026	16	1182	5	154	1357	689	36	99	534	1357

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2017	27	-27	-2	-2
Mar 2018	28	-5	-20	3
Mar 2019	49	5	-50	4
Mar 2020	117	-25	-29	62
Mar 2021	76	-47	-15	15
Mar 2022	49	-60	150	139
Mar 2023	64	-124	-10	-70
Mar 2024	113	-174	-22	-83
Mar 2025	165	-152	-8	4
Mar 2026	186	-176	-10	0

Key ratios

Historical financial ratios

Category	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	99	92	79	60	69	79	67	71	70	97
Inventory Days	113	85	77	130	206	172	234	140	205	229
Days Payable	121	112	110	130	145	91	130	98	129	159
Cash Conversion Cycle	91	64	45	61	130	160	171	114	146	167
Working Capital Days	-69	-50	-5	-40	28	117	168	157	144	147
ROCE %	—	14%	37%	50%	60%	43%	19%	22%	27%	25%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of SUPRIYA LIFESCIENCE LTD (SUPRIYA)?

The reported market capitalisation for SUPRIYA LIFESCIENCE LTD (SUPRIYA) is ₹7,131Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of SUPRIYA?

The current price shown for SUPRIYA LIFESCIENCE LTD (SUPRIYA) on Fincrux is ₹886 with a 52-week high/low of ₹1,086/546.

What is the P/E ratio of SUPRIYA LIFESCIENCE LTD (SUPRIYA)?

The stock P/E for SUPRIYA LIFESCIENCE LTD (SUPRIYA) is 35.9 on Fincrux, with ROE at 19.1% and ROCE at 25.2%.

What were SUPRIYA latest quarterly results?

For Jun 2026, SUPRIYA LIFESCIENCE LTD (SUPRIYA) reported sales ₹190 Cr and net profit ₹24 Cr (figures in ₹ crore unless noted).

What are SUPRIYA annual sales and net profit?

For TTM, SUPRIYA LIFESCIENCE LTD (SUPRIYA) shows sales of ₹873 Cr and net profit of ₹198 Cr on the Fincrux profit & loss statement.

Who owns SUPRIYA LIFESCIENCE LTD (SUPRIYA)?

Latest shareholding for SUPRIYA LIFESCIENCE LTD (SUPRIYA) on Fincrux: Promoters 68.30% (Sep 2026), FIIs 6.45% (Sep 2026), DIIs 5.47% (Sep 2026), Public 19.80% (Sep 2026), No. of Shareholders 78,561% (Sep 2026).

Where can I find SUPRIYA LIFESCIENCE LTD (SUPRIYA) financials?

SUPRIYA LIFESCIENCE LTD (SUPRIYA) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show SUPRIYA balance sheet and cash flow?

Yes. The SUPRIYA LIFESCIENCE LTD (SUPRIYA) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 6:08